Enzon Pharmaceuticals, Inc. (ENZN) Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends
4/24/2013 10:11:38 AM
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) Reports Fourth Quarter and Full Year 2012 Results
3/19/2013 8:59:56 AM
More...
|
Enzon Pharmaceuticals (Piscataway, New Jersey) (ENZN) Announces Special Dividend
11/30/2012 10:38:00 AM
More...
|
Enzon Pharmaceuticals (Piscataway, New Jersey) (ENZN) Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China
11/8/2012 9:22:19 AM
More...
|
Enzon Pharmaceuticals (Piscataway, New Jersey) (ENZN) Reports Second Quarter 2012 Results
8/1/2012 8:45:11 AM
More...
|
Enzon Pharmaceuticals (Piscataway, New Jersey) (ENZN) Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
6/19/2012 10:33:49 AM
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China
5/7/2012 8:51:56 AM
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) Reports First Quarter 2012 Results
5/2/2012 8:27:40 AM
More...
|
Enzon Pharmaceuticals (Piscataway, New Jersey) (ENZN) Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer Meeting
11/14/2011 9:09:37 AM
More...
|
Enzon Pharmaceuticals (Piscataway, New Jersey) (ENZN) Reports 3rd Quarter 2011 Results
11/4/2011 8:18:54 AM
More...
|
|